Journal of Vaccine Research 2024, Vol.14, No.4, 157-169 http://medscipublisher.com/index.php/jvr 168 Ng H.I., Fernando G.J.P., Depelsenaire A.C.I., and Kendall M.A.F., 2016, Potent response of QS-21 as a vaccine adjuvant in the skin when delivered with the Nanopatch, resulted in adjuvant dose sparing, Scientific Reports, 6(1): 29368. https://doi.org/10.1038/srep29368 PMid:27404789 PMCid:PMC4941647 Nguyen Q.T., and Choi Y.K., 2021, Targeting antigens for universal influenza vaccine development, Viruses, 13(6): 973. https://doi.org/10.3390/v13060973 PMid:34073996 PMCid:PMC8225176 Paules C.I., Marston H.D., Eisinger R., Baltimore D., and Fauci A.S., 2017, The pathway to a universal influenza vaccine, Immunity, 47(4): 599-603. https://doi.org/10.1016/j.immuni.2017.09.007 PMid:29045889 Petrie J.G., and Gordon A., 2018, Epidemiological studies to support the development of next generation influenza vaccines, Vaccines, 6(2): 17. https://doi.org/10.3390/vaccines6020017 PMid:29587412 PMCid:PMC6027373 Pica N., and Palese P., 2013, Toward a universal influenza virus vaccine: prospects and challenges, Annual Review of Medicine, 64(1): 189-202. https://doi.org/10.1146/annurev-med-120611-145115 PMid:23327522 Qiu X., Duvvuri V.R., and Bahl J., 2019, Computational approaches and challenges to developing universal influenza vaccines, Vaccines, 7(2): 45. https://doi.org/10.3390/vaccines7020045 PMid:31141933 PMCid:PMC6631137 Sangesland M., and Lingwood D., 2021, Antibody focusing to conserved sites of vulnerability: the immunological pathways for 'universal'influenza vaccines, Vaccines, 9(2): 125. https://doi.org/10.3390/vaccines9020125 PMid:33562627 PMCid:PMC7914524 Sesterhenn F., Yang C., Bonet J., Cramer J.T., Wen X., Wang Y., Chiang C.I., Abriata L.A., Kucharska I., Castoro G., Vollers S.S., Galloux M., Dheilly E., Rosset S., Corthésy P., Georgeon S., Villard M., Richard C.A., Descamps D., Delgado T., Oricchio E., Rameix-Welti M.A., Más V., Ervin S., Eléouët J.F., Riffault S., Bates J.T., Julien J.P., Li Y.X., Jardetzky T., Krey T., and Correia B.E., 2020, De novo protein design enables the precise induction of RSV-neutralizing antibodies, Science, 368(6492): eaay5051. https://doi.org/10.1126/science.aay5051 PMid:32409444 PMCid:PMC7391827 Sharma S., Kumari V., Kumbhar B. V., Mukherjee A., Pandey R., and Kondabagil K., 2021, Immunoinformatics approach for a novel multi-epitope subunit vaccine design against various subtypes of Influenza A virus, Immunobiology, 226(2): 152053. https://doi.org/10.1016/j.imbio.2021.152053 PMid:33517154 Skarlupka A.L., Bebin-Blackwell A.G., Sumner S.F., and Ross T.M., 2021, Universal influenza virus neuraminidase vaccine elicits protective immune responses against human seasonal and pre-pandemic strains, Journal of Virology, 95(17): 10-1128. https://doi.org/10.1128/JVI.00759-21 PMid:34160258 PMCid:PMC8354223 Tao P., Zhu J., Mahalingam M., Batra H., and Rao V.B., 2019, Bacteriophage T4 nanoparticles for vaccine delivery against infectious diseases, Advanced Drug Delivery Reviews, 145: 57-72. https://doi.org/10.1016/j.addr.2018.06.025 PMid:29981801 PMCid:PMC6759415 Tregoning J.S., Russell R.F., and Kinnear E., 2018, Adjuvanted influenza vaccines, Human Vaccines and Immunotherapeutics, 14(3): 550-564. https://doi.org/10.1080/21645515.2017.1415684 PMid:29232151 PMCid:PMC5861793 Viboud C., Gostic K.M., Nelson M.I., Price G., Perofsky A., Sun K., Trovão N.S., Cowling B.J., Epstein S.L., and Spiro D.J., 2020, Beyond clinical trials: Evolutionary and epidemiological considerations for development of a universal influenza vaccine, PLoS Pathogens, 16(9): e1008583. https://doi.org/10.1371/journal.ppat.1008583 PMid:32970783 PMCid:PMC7514029 Wang W.C., Sayedahmed E.E., Sambhara S., and Mittal S.K., 2022, Progress towards the development of a universal influenza vaccine, Viruses, 14(8): 1684. https://doi.org/10.3390/v14081684 PMid:36016306 PMCid:PMC9415875 Wong T.M., and Ross T.M., 2016, Use of computational and recombinant technologies for developing novel influenza vaccines, Expert Review of Vaccines, 15(1): 41-51. https://doi.org/10.1586/14760584.2016.1113877 PMid:26595182 Xu L.H., Feng T.T., and Fang K.Y., 2024, Safety and efficacy of mRNA vaccines: insights from clinical trials, International Journal of Clinical Case Reports, 14(3): 117-131. https://doi.org/10.5376/ijccr.2024.14.0014
RkJQdWJsaXNoZXIy MjQ4ODYzNQ==